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Abstract
With age and menopause there is a shift in adipose distribution from gluteo-femoral to abdominal depots in women.
Associated with this redistribution of fat are increased risks of type 2 diabetes and cardiovascular disease. Glucocorticoids
influence body composition, and 11b-hydroxysteroid dehydrogenase type 1 (11bHSD1) which converts inert cortisone to
active cortisol is a putative key mediator of metabolic complications in obesity. Increased 11bHSD1 in adipose tissue may
contribute to postmenopausal central obesity. We hypothesized that tissue-specific 11bHSD1 gene expression and activity
are up-regulated in the older, postmenopausal women compared to young, premenopausal women. Twenty-three pre- and
23 postmenopausal, healthy, normal weight women were recruited. The participants underwent a urine collection, a
subcutaneous adipose tissue biopsy and the hepatic 11bHSD1 activity was estimated by the serum cortisol response after
an oral dose of cortisone. Urinary (5a-tetrahydrocortisol+5b-tetrahydrocortisol)/tetrahydrocortisone ratios were higher in
postmenopausal women versus premenopausal women in luteal phase (P,0.05), indicating an increased whole-body
11bHSD1 activity. Postmenopausal women had higher 11bHSD1 gene expression in subcutaneous fat (P,0.05). Hepatic first
pass conversion of oral cortisone to cortisol was also increased in postmenopausal women versus premenopausal women in
follicular phase of the menstrual cycle (P,0.01, at 30 min post cortisone ingestion), suggesting higher hepatic 11bHSD1
activity. In conclusion, our results indicate that postmenopausal normal weight women have increased 11bHSD1 activity in
adipose tissue and liver. This may contribute to metabolic dysfunctions with menopause and ageing in women.
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Introduction
With age, and menopause, in women there is a shift in adipose
distribution from gluteo-femoral to abdominal depots [1,2].
Abdominal fat accumulation, and menopause per se, links to an
increased risk of insulin resistance, type 2 diabetes, and future
cardiovascular disease [3,4]. The decrease in estradiol (E2) levels
that occur with menopause might be an underlying factor of these
dysmetabolic features [5]. However, other steroid hormones,
notably glucocorticoids, may directly or indirectly influence body
composition and the risk of cardiovascular disease [6].
Circulating cortisol levels are tightly controlled by forward drive
through hypothalamic-pituitary factors and negative feedback by
cortisol[7]. Glucocorticoid excess due to tumours producing ACTH
or cortisol, as occurs in Cushing’s syndrome, causes central obesity,
type 2 diabetes, and cardiovascular disease. In idiopathic obesity,
circulating cortisol levels are essentially normal, although there may
be a subtle impairment in the negative feedback by endogenous
cortisol [8]. However, it has been suggested that changes in
glucocorticoid metabolism may contribute to a Cushing’s-like
phenotype linked to abdominal obesity [6].
The availability of active glucocorticoid in different tissues is
modulated through enzymatic interconversion between cortisone
and cortisol by 11b-hydroxysteroid dehydrogenase type 1 and 2
(11bHSD1/2) [7]. 11bHSD1 activates cortisone to cortisol and is
widely expressed with high expression in liver, adipose tissue and
lung. 11bHSD2 perform the opposite reaction and is present in
mineralocorticoid target tissues e.g. the kidney [7]. In idiopathic
obesity, 11bHSD1 levels are increased in subcutaneous adipose
tissue and reduced in liver [6,9]. The physiological relevance of
alterations in the activity of this enzyme has been demonstrated in
several animal models. 11bHSD1 knockout mice are protected
from visceral fat accumulation when fed a high-fat diet [10], while
selective over-expression of 11bHSD1 in adipose tissue results in
abdominal obesity, insulin resistance, and hypertension [11,12].
Liver-specific over-expression of the enzyme results in a non-obese
phenotype with increased hepatic fat content linked to mild insulin
resistance, dyslipidemia, and hypertension [13].
Circulating cortisol levels are unaltered in post- versus
premenopausal women [14]. Although not confirmed in humans
[15], E2 attenuates 11bHSD1 expression and enzyme activity in
the liver and testis of rodents, [16–18]. This suggest that the
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dysmetabolic features including fat redistribution, elevated blood
pressure, and dyslipidemia commonly seen after menopause may
at least partly be mediated through tissue-specific alterations in
cortisol levels via increased 11bHSD1.
We hypothesized that 11bHSD1 expression and activity are
increased in adipose tissue and/or liver in postmenopausal versus
premenopausal normal weight women.
Materials and Methods
Subjects
Twenty-three premenopausal and 23 postmenopausal, healthy,
normal weight women were recruited by advertisements in the
local newspapers and within the Umea˚ University Hospital and
campus areas. Exclusion criteria were: diabetes, thyroid dysfunc-
tion, hepatic and renal disease, use of tobacco, hormonal
contraceptives, systemic gonadal hormone replacement therapy,
or oral glucocorticoid medication. None of the postmenopausal
women reported menstrual periods within the last 12 months. One
premenopausal woman used inhaled steroids for asthma (budeso-
nide, 400 mg/24 h). Three postmenopausal women had well-
controlled hypertension treated with b-blockers, diuretics, or
calcium antagonist, one took tolterodine for urinary incontinence
and bisphosphonates for osteoporosis, and two used topical E2 or
estriol treatment.
Ethics Statement
The study was approved by the Umea˚ University Ethical
Committee and all subjects gave written, informed consent before
entering the study.
Clinical protocol
Premenopausal women were evaluated during both follicular
and luteal phases of the menstrual cycle to investigate the possible
effects of hormonal fluctuations. Menstrual phase or postmeno-
pausal status was confirmed by measuring serum E2 and
progesterone levels. Anthropometric measurements, urine collec-
tions, adipose tissue biopsies, and hepatic cortisone conversion
tests were performed on separate days.
Weight to the nearest 0.1 kg (with subjects wearing light clothes)
and height and waist circumference to the nearest 0.5 cm was
measured. Blood pressure was measured in the sitting position
after 5 minutes rest with a mercury sphygmomanometer.
Urine was collected for 24 h, measured to the nearest ml, and
aliquots stored without preservatives at 220uC until analyzed.
Approximately 2 g of periumbilical superficial subcutaneous
adipose tissue was excised under local anaesthesia with lidocaine
(XylocaineH without adrenaline, AstraZeneca, Sweden) after an
overnight fast. Tissue was snap frozen in liquid nitrogen within 5
minutes after removal, and stored at 280uC until further analyses.
For the hepatic cortisone conversion test, the subjects took an
oral dose of 1 mg dexamethasone (2 tablets of 0.5 mg Decadro-
neH, Merck & Co., Sweden) at 2300 h in order to suppress
endogenous cortisol production and fasted overnight. Venous
blood samples for baseline cortisol levels were drawn at
approximately 0800–0900 h, followed by 25 mg oral cortisone
acetate (CortalH 25 mg, N.V. Organon Oss Holland). Blood
samples for serum cortisol analyses were then drawn every 30
minutes during the following four hours.
Venous blood samples for routine laboratory tests were drawn
at the time of anthropometric measurements. Venous blood
samples for serum analyses (described below) were drawn in the
mornings of the adipose tissue biopsies and cortisone conversion
tests after at least eight hours of fasting.
Laboratory Methods
RNA extraction and quantification. Total RNA was
extracted according to the manufacturer’s instructions from
approximately 450 mg of adipose tissue using the RNeasyH lipid
tissue midi kit (Qiagen Nordic, Qiagen House, West Sussex, UK).
RNA concentrations were measured on a ND-1000 Spectro-
photometer (NanoDrop Technologies, Bancroft Building,
Wilmington, DE, USA) and integrity was evaluated on a 1%
agarose electrophoretic gel and visualized with ethidium bromide
under UV-light.
SpectrophotometerTwo micrograms of RNA was reverse
transcribed using TaqManH Reverse Transcription Reagents
(Roche Molecular Systems, Inc., Branchburg, NJ, USA). Real-
time PCR was carried out on an ABI PrismH 7000 Sequence
Detection System (Applied Biosystems) according to manufactur-
er’s instructions using Universal PCR Master Mix 2X (Roche
Molecular Systems, Inc., Branchburg, NJ, USA) and TaqMan
Gene expression assays for target genes 11bHSD1 (assay
No. Hs00194153_m1), aromatase (assay No. Hs00240671_m1),
and the endogenous control Cyclophilin A (PPIA) (assay
No. Hs99999904_m1) (Applied Biosystems, Foster City, CA,
USA). All reactions were performed in triplicate and non-template
controls were included on every plate. A standard curve was
included on each plate for relative quantification. Data were
normalized against PPIA, which had the lowest coefficient of
variation and the best stability value, based on the Normfinder
algorithm (http://www.mdl.dk/publicationsnormfinder.htm) out
of three tested endogenous controls (PPIA, LRP10 and RPLP0,
data not shown), previously found to be suitable for human
adipose tissue analyses [19].
In vitro adipose 11bHSD1 enzyme activity assay. 11b-
HSD1 protein in adipose tissue was quantified by measuring
enzyme activity in the dehydrogenase direction, which is the
preferred reaction in tissue homogenates with excess cofactor
[20,21]. Adipose tissue (300 mg) was homogenized in 900 ml ice-
cold buffer (10% glycerol, 300 mM NaCl, 1 mM EDTA, 50 mM
Tris, pH 7.4) and 0.1 mM dithiothreitol and centrifuged at
12,0006g for 15 min at 4uC. Total protein concentrations were
determined using the Bradford technique (Bio-Rad protein assay,
Bio-Rad Laboratories Inc., Herculus, CA, USA). Duplicate
samples of 3 mg/ml of protein were incubated at 37uC with
10 mM NADP and 50 nM [1,2,6,7-3H]4-cortisol for 24 h.
Samples were withdrawn at 12, 16, 20, and 24 h and frozen at
280uC. Subsequently, glucocorticoids were extracted with
dichloromethane, the organic phase evaporated, extracts
dissolved in ethanol and separated by thin layer chromatography
(on TLC aluminium sheets, 20620 cm, Silica gel 60 F254, Merck
KGaA, Darmstadt, Germany, mobile phase; chloroform and
ethanol (92:8)). Radio-labelled glucocorticoids were detected by
exposure of the TLC sheet to a tritium storage phosphor screen,
subsequently scanned in a TyphoonTM 9400 scanner (both GE
Healthcare Europe GmbH, Germany). 11bHSD1 activity was
expressed as percent conversion of cortisol to cortisone.
Urinary corticosteroid metabolites. Cortisol, cortisone, 5a-
tetrahydrocortisol (5a-THF), 5b-THF, and 5b-tetrahydrocortisone
(THE) concentrations were analyzed by gas chromatography and
electron impact mass spectrometry as previously described [22].
Serum analyses. Liver transaminases were measured in the
samples drawn at the time of anthropometric measurements
(menstrual phase not determined). Estradiol, progesterone and
cortisol were measured in samples drawn both at the biopsy and at
the cortisone conversion test. All other analyses were made in
samples drawn on the morning of the adipose tissue biopsy to avoid
interference with the dexamethasone suppression administered in
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advance of the cortisol conversion test. Serum cortisol,
progesterone, sex hormone-binding globulin (SHBG), and insulin
were analyzed by electrochemiluminescence immunoassays, on a
Modular Analytics E170 (all from Roche AB, Stockholm, Sweden).
Serum free testosterone was measured using a radioimmunoassay,
Coat-a-countH, (Siemens Healthcare Diagnostics, Deerfield, IL,
USA). Glucose, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), cholesterol, triglycerides, and HDL and
LDL cholesterol were analyzed on a VITROSH Ektachem 950 IRC
(Johnson & Johnson, Langhorne, PA, USA) using colorimetric
assays. Apolipoprotein A1 (ApoA1) and Apo B was analyzed with
immunoturbidimetric technique on a Hitachi 911 analyzer (Roche
AB, Stockholm, Sweden). HOMA-IR (Homeostasis Model
Assessment for Insulin Resistance) was calculated using the
HOMA calculator v2.2 available at www.dtu.ox.ac.uk. E2 was
measured using an ultra sensitive radioimmunoassay (ESTR-US-
CT, CIS bio international, Gif-sur-Yvette, Cedex, France) (intra-
and interassay coefficients of variation (CV); 2.8–18.1% and 5.8–
17.6%, respectively).
Statistical Analyses
Data are shown as mean6SD, unless otherwise indicated, and
were natural log-transformed when necessary to achieve normal
distribution. Student’s t-tests were used to compare means
between the groups and paired Student’s t-tests to compare
follicular and luteal phase samples in the premenopausal group.
Associations between variables, including follicular phase pre-
menopasual and postmenopausal women, were examined with
Pearson correlation tests with adjustments for waist circumference,
BMI, and menopausal status in partial correlation analyses. The
effect of, and possible interaction between, waist circumference or
BMI and menopausal status was tested with linear regression.
Repeated-measures ANOVA was employed to test the effect of
menopausal status on adipose enzyme activity. Statistical calcula-
tions were carried out using the SPSS software (release 14.0.1,
SPSS Inc., 233 S. Wacker Drive, Chicago, IL). Premenopausal
women found not to be in the anticipated menstrual phase were
excluded in the statistical calculations for that particular test.
Results
Subject Characteristics (Tables 1 and 2)
BMI and waist circumference did not differ between the
menopausal groups. E2, progesterone, and free testosterone levels
were significantly lower in postmenopausal vs. premenopausal
women regardless of menstrual phase. Systolic blood pressure,
serum total cholesterol and cholesterol sub-fractions (except HDL;
only vs. luteal phase), triglyceride levels, and liver transaminases
were higher in postmenopausal women, while HOMA-IR was
lower, mainly due to lower fasting insulin levels among
postmenopausal women. Within the menstrual cycle, LDL,
apolipoprotein B, and cholesterol levels were increased in the
follicular vs. luteal phase.
Urinary Corticosteroid Metabolites (Table 3)
Total glucocorticoid urinary metabolite excretion did not differ
between groups, indicative of unaltered glucocorticoid production
rate with menopause. The (5a-THF+5b-THF)/THE ratio was
significantly higher in postmenopausal vs. premenopausal women
in luteal phase, indicating a higher total body 11bHSD1 activity in
postmenopausal women; this difference remained after adjustment
for BMI and waist circumference. The (5a-THF+5b-THF)/THE
ratio correlated positively with diastolic blood pressure (R = 0.34,
P,0.05) and serum LDL (R = 0.31, P,0.05) and negatively with
serum E2 (R =20.34, P,0.05); these associations did not remain
after adjustment for BMI, waist circumference, and menopausal
group (Table 4). Postmenopausal women had higher urinary 5b-
THF excretion than premenopausal women regardless of
menstrual phase, with lower 5a-THF/5b-THF ratio compared
to premenopausal women in the follicular phase; these differences
persisted after adjustment for waist circumference and BMI.
11bHSD1 in Subcutaneous Adipose Tissue
Among premenopausal women 11bHSD1 expression was
higher in luteal vs. follicular phase of the menstrual cycle
(Fig. 1A). Postmenopausal women had a higher adipose 11bHSD1
expression vs. follicular phase premenopausal women. 11bHSD1
expression in adipose tissue correlated with waist circumference
(R = 0.56, P,0.001) but not BMI (Table 4). Linear regression
analysis showed that waist circumference and menopausal group
both independently affect the 11bHSD1 expression in adipose
tissue; b= 0.493, P,0.001 and b=20.298, P,0.05, respectively.
11bHSD1 enzyme activity showed a close correlation with
11bHSD1 mRNA expression (Fig. 1B) but did not differ
significantly between groups (Fig. 1C). Enzyme activity was
positively associated with waist circumference (R = 0.66,
P,0.001), this remained after adjustment for BMI and meno-
pausal group (Table 4).
11bHSD1 expression correlated positively with systolic blood
pressure, cholesterol, LDL cholesterol, triglycerides, and adipose
aromatase expression (Table 4). In addition there was a negative
correlation with HDL cholesterol (Table 4). Of these correlations,
only the associations with aromatase and HDL cholesterol
remained after adjustment for BMI, waist circumference, and
menopausal group. A similar pattern was shown for adipose
11bHSD1 activity which correlated positively with LDL choles-
terol and aromatase and negatively with HDL cholesterol
(Table 4); only the latter remained after adjustments.
In Vivo Hepatic 11bHSD1 Activity
At 30 minutes post oral cortisone ingestion, serum cortisol levels
were higher in postmenopausal women than premenopausal
women in the follicular phase of the menstrual cycle (P,0.01,
Fig. 2); the difference remained after adjustment for BMI and waist
Table 1. Subject characteristics.
Premenopausal Postmenopausal
N 23 23
Age (yrs) 2765 6364***
BMI (kg/m2) 23.361.8 23.461.9
Waist circumference (cm) 79.767.3 82.865.5
SBP (mmHg) 112611 127614***
DBP (mmHg) 6969 7469
AST (ukat/L) 0.3260.06 0.4160.07***
ALT (ukat/L) 0.3160.09 0.4360.07***
HOMA-IR 0.9360.34 0.6660.18**
Glucose (mmol/L) 4.6260.35 4.7260.40
Insulin (mIU/L) 7.362.4 5.161.7***
SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate
aminotransferase; ALT alanine aminotransferase; HOMA-IR, Homeostasis Model
Assessment for Insulin Resistance.
**P,0.01 and ***P,0.001 vs. premenopausal women.
doi:10.1371/journal.pone.0008475.t001
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circumference. This indicates a faster conversion of cortisone to
cortisol on first pass through the liver, suggesting increased hepatic
11bHSD1 reductase activity in the postmenopausal women.
Similar to the measures of adipose 11bHSD1, serum cortisol
levels at 30 min post cortisone ingestion, correlated positively with
systolic blood pressure, serum cholesterol, and LDL cholesterol.
The associations to serum cholesterol and LDL cholesterol
remained after adjustment for BMI, waist circumference, and
menopausal group (Table 4). There were also negative correlations
with serum estradiol and testosterone levels before adjustments
(Table 4).
Discussion
The postmenopausal women in this study had a higher urinary
cortisol/cortisone metabolites ratio suggestive of increased total
body 11bHSD1 activity. Importantly, we found higher transcript
levels of the glucocorticoid-generating enzyme 11bHSD1 in
Table 3. Urinary corticosteroid metabolites.
Premenopausal (follicular phase) Premenopausal (luteal phase) Postmenopausal
N 18 18 23
THE (mg/day) 2,48061319 2,65361988 2,5076698
5bTHF (mg/day) 1,0106522 9866643 1,5866432***{{
5aTHF (mg/day) 1,1176750 1,0236886 9756427
Cortisone (mg/day) 116636 110645 113634
Cortisol (mg/day) 117649 93642 91632*
(5bTHF+5aTHF)/THE 0.9660.59 0.8760.47 1.0860.28{
5aTHF/5bTHF 1.4161.48 1.0760.70 0.6960.44*
5a-THF/cortisol 9.4965.23 10.6168.57 11.5966.24
5b-THF/cortisol 9.1765.17 11.5967.68 19.6968.18***{{
THE/cortisone 21.3669.79 23.16613.29 24.12611.43
Cortisol/cortisone 1.0160.24 0.8960.26 0.8660.34*
Total urinary metabolites 4,84062,341 4,86563,193 5,27361,002
Three women in each premenopausal group were found not to be in the anticipated phase of the menstrual cycle, one woman in follicular phase did not comply with
the instructions of the urine collection and two women in luteal and one woman in follicular phase of the menstrual cycle did not collect urine. *P,0.05 and ***P,0.001
vs. follicular phase.
{P,0.05 and {{P,0.01 vs. luteal phase. THF, tetrahydrocortisol; THE, tetrahydrocortisone.
doi:10.1371/journal.pone.0008475.t003
Table 2. Circulating levels of steroids and lipids and adipose aromatase transcript levels.
Premenopausal (follicular phase) Premenopausal (luteal phase) Postmenopausal
N 19 17 23
Circulating steroids
Estradiol (pmol/L) 2006142{ 3486141 2066***{{{
Progesterone (nmol/L) 2.3060.79{{{ 32.53616.44 1.3260.47***{{{
Testosterone/SHBG 0.02360.02 0.02160.019 0.01160.006*{
Cortisol (nmol/L) 4766184 7386207 4726141
Blood lipids
Cholesterol (mmol/L) 4.160.8{ 3.961.0 6.261.1***{{{
HDL cholesterol (mmol/L) 1.6660.39 1.5460.38 1.8360.31{
LDL cholesterol (mmol/L) 2.1360.62{{ 2.0860.72 3.9161.02***{{{
Triglycerides (mmol/L) 0.7160.17 0.6660.14 1.0860.34***{{{
ApoA1 (mg/L) 1,3916211 1,3016219 1,5766176**{{{
ApoB (mg/L) 7356156{{{ 7176200 1,2126262**{{{
Adipose gene expression
Aromatase 11,20367565 11,52267454 11,86365506
One woman in follicular phase and three in the luteal phase of the menstrual cycle did not have the biopsy and three women in each premenopausal group were found
not to be in the correct menstrual phase. 11bHSD1, 11b-hydroxyteroid dehydrogenase type 1; PPIA, Cyclophilin A; SHBG, Sex hormone-binding globulin; HDL, high-
density lipoprotein; LDL low-density lipoprotein; ApoA1, Apolipoprotein A-1; ApoB, Apolipoprotein B. N = 16 for luteal phase blood lipid data.
*P,0.05, **P,0.01 and ***P,0.001 vs. follicular phase.
{P,0.05, {{P,0.01 and {{{P,0.001 vs. luteal phase.
doi:10.1371/journal.pone.0008475.t002
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subcutaneous fat with concomitantly increased first-pass conver-
sion of cortisone to cortisol, suggesting increased hepatic
11bHSD1 activity. These findings support an elevation in
11bHSD1 activity in older menopausal women in both adipose
tissue and liver, resulting in a tissue-specific increase in
glucocorticoid exposure despite unaltered circulating cortisol
levels. Waist circumference was closely linked with increased
adipose tissue 11bHSD1 transcript levels and enzyme activity.
However, 11bHSD1 transcript levels in adipose tissue were also
independently affected by menopausal/age group. Additionally,
the differences in hepatic and whole-body 11bHSD1 activity
between premenopausal and postmenopausal women were
independent of waist circumference, suggesting an effect of age/
menopausal group over and above the associations between
centralization of body fat and 11bHSD1.
Whether these changes are related to age and/or menopause
per se cannot be determined from this cross-sectional study.
Notably, decreased circulating estrogen levels due to ovariectomy
or menopause in rodents and/or humans results in increased body
fat mass with central distribution [23,24]. This change in body
composition, linked to insulin resistance and increased risk of
cardiovascular disease in postmenopausal women, can be reversed
by estrogen replacement therapy [23,24]. However, data from
studies of the effects of estrogen on 11bHSD1 in adipose tissue are
sparse and partly conflicting, and included mixed cohorts of both
pre- and postmenopausal women, with varying BMI, and/or a
limited number of samples [25–27]. In our study serum E2 levels
correlated negatively with measures of both whole body and
hepatic 11bHSD1 activity, supporting a down-regulatory effect of
E2. However, this is confounded by putative effects of age/
menopausal status and body composition. Notably, we did not find
an association between serum E2 levels and adipose 11bHSD1
expression or activity, which may suggest tissue-specific differences
in the interaction between estrogen and 11bHSD1.
In contrast, we found a positive association between aromatase
and 11bHSD1 gene expression in adipose tissue, independent of
adiposity and menopausal group. In postmenopausal women,
aromatase activity is the main source of E2, and aromatase
expression has been shown to increase after menopause [25,28].
The positive correlation with aromatase hence suggests an up-
regulatory effect of E2 on 11bHSD1 expression in adipose tissue,
but this may also be related to glucocorticoids driving the
promoter activity of the aromatase gene [29]. Therefore, our
observations regarding E2 and 11bHSD1 are inconsistent and
need further investigation to elucidate whether estrogen deficiency
underpins elevated 11bHSD1 in the postmenopausal state.
There are alterations in cytokines and other hormones with age
and menopause which may influence 11bHSD1 levels [30]. With
menopause there is an increased immune activation with increased
serum levels of proinflammatory cytokines [31]. Interestingly,
cytokines such as TNF-a influence 11bHSD1 expression and
activity [32], and it would therefore be of interest to study possible
associations between immune responses and glucocorticoid
activation in these subjects. An alternative explanation related to
Table 4. Bivariate correlations for adipose 11bHSD1 expression and activity, urinary THFs/THE and hepatic 11bHSD1 activity versus
anthropometric data, sex steroids, hormones and gene expression of aromatase.
Correlation coefficients (Pearson correlation)
Adipose 11bHSD1mRNA Adipose 11bHSD1-EA Urinary THFs/THE Hepatic 11bHSD1-EA
N 42 33 41 40
11bHSD-EA 0.85*** n.a. n.a. n.a.
Anthropometric variables
Waist circumference 0.56*** 0.66*** 0.31 20.01
BMI 0.10 0.25 0.07 20.15
SBP 0.44** 0.30 0.27 0.38*
DBP 0.22 0.17 0.34* 0.16
Blood analyses
Insulin 20.13 0.07 20.17 20.09
Glucose 0.04 0.07 20.08 20.01
Cholesterol 0.39* 0.20 0.29 0.58***, {
HDL cholesterol 20.35*, { 20.48**, { 20.01 0.18
LDL cholesterol 0.50** 0.35* 0.31* 0.58***, {
Triglycerides 0.34* 0.21 0.17 0.29
Sex steroids
Aromatase mRNA 0.58***, { 0.44* n.a. n.a.
Estradiol 20.30 20.16 20.34* 20.48**
Progesterone 20.21 20.09 20.20 20.08
Testosterone/SHBG 0.02 0.10 20.18 20.33*
Premenopausal women in follicular phase of the menstrual cycle and postmenopausal women were included. Enzyme activity was measured as percent conversion of
cortisol to cortisone after 24 h incubation. Urinary THFs/THE gives a measure of whole body 11bHSD1 activity. Hepatic 11bHSD1 activity was measured as serum cortisol
30 minutes after oral cortisone. 11bHSD1, 11b-hydroxysteroid dehydrogenase type 1; EA, Enzyme activity; THFs/THE, (5a-tetrahydrocortisol+5b-tetrahydrocortisol)/5b-
tetrahydrocortione; SBP, systolic blood pressure; DBP, diastolic blood pressure, n.a., not applicable. Data are correlation coefficients (Pearson correlation).
*P,0.05, **P,0.01, and ***P,0.001.
{Association significant after adjusting for waist circumference, BMI, and menopausal group (partial correlation).
doi:10.1371/journal.pone.0008475.t004
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menopausal status is progesterone deficiency, which has not been
studied in detail. Notably, we did not find any associations
between serum progesterone levels and measures of 11bHSD1
expression/activity. However, among premenopausal women
adipose 11bHSD1 expression was higher in the luteal phase of
the menstrual cycle, which is characterized by high serum estrogen
and progesterone levels, compared to the follicular phase. On the
other hand, consistent with previous studies [15] we did not find
differences in urinary steroid ratios, or liver 11bHSD1 activity
within the menstrual cycle. Further experimental analyses of the
role of progesterone in tissue-specific glucocorticoid activation
therefore seem warranted.
11bHSD1 activity and mRNA expression in adipose tissue were
strongly correlated but there was no significant difference in
11bHSD1 activity between groups. The lack of a statistically
significant difference may at least partly be due to low power as
there were fewer samples available for these analyses due to lack of
tissue homogenate. Importantly, 11bHSD1 activity is relatively
low in this BMI range (compared to levels seen in obese subjects,
[21]) and in line with this, the previously reported association
between 11bHSD1 activity/expression and BMI [9,21] was not
detected in this study cohort.
Our results from the hepatic cortisone-to-cortisol conversion test
indicate higher 11bHSD1 activity in the liver of postmenopausal
women. This contrast with previous observations in overweight
individuals, where we and others have suggested a reduced
11bHSD1 activity in liver in combination with up-regulation of
activity/expression in adipose tissue [9,20,21]. Interestingly,
gonadal dysfunction and increased body fat percentage with
normal body weight is linked to increased hepatic cortisone
conversion in patients with myotonic dystrophy [33]. These
patients develop fatty livers and, although liver fat content was not
estimated in the present study, the postmenopausal women of our
study had significantly higher serum levels of liver enzymes (AST,
ALT), which is linked to increased liver fat content.
The balance between cortisol and cortisone and their
metabolites in urine has often been used as an estimation of the
whole body activity of 11bHSD1. We found a higher THFs/THE
ratio in postmenopausal women, which is in part explained by
their higher 5bTHF levels. This is consistent with an overall
increase in 11bHSD1 activity with menopause/older age, and
similar to what we have previously observed with increasing BMI
in pre-/perimenopausal women, but contrary to the findings in a
Figure 1. Subcutaneous adipose tissue 11bHSD1. A 11bHSD1
transcript levels were normalized to endogenous control Cyclophilin A.
*P,0.05, ** P,0.01, N=19, 17, and 23 for the premenopausal follicular
(%), luteal (&), and postmenopausal (m) groups, respectively. One
woman in follicular phase and three in the luteal phase of the menstrual
cycle did not have the biopsy and three women in each premenopausal
group were found not to be in the correct phase. Data were natural log-
transformed to achieve normal distribution. B Correlation between
adipose 11bHSD1 activity after 24 hr incubation (percent conversion) and
adipose 11bHSD1 mRNA expression (relative to Cyclophilin A). Premen-
opausal follicular (%), luteal (&), and postmenopausal women (m). Linear
regression line is shown for the postmenopausal group, dotted lines
denotes the 95% confidence interval. C Subcutaneous adipose tissue
11bHSD1 activity was measured as percent conversion of cortisol to
cortisone over time in tissue homogenates, protein concentration 3 mg/
ml. N= 13, 10, and 20 for premenopausal follicular (%), luteal (&), and
postmenopausal women (m), respectively. There were no significant
differences between the groups. Data were ln-transformed to achieve
normal distribution and are shown as means6SEM.
doi:10.1371/journal.pone.0008475.g001
Figure 2. Hepatic 11bHSD1 activity. Serum cortisol levels after
overnight dexamethasone suppression and oral cortisone intake
(25 mg). Postmenopausal women (m, N = 23) had higher serum cortisol
levels at 30 min post cortisone intake than premenopausal women in
follicular phase of the menstrual cycle (%, N = 17). *P,0.05 and
**P,0.01 for postmenopausal vs. premenopausal follicular phase.
Luteal phase, &, N = 16. Data are means6SEM.
doi:10.1371/journal.pone.0008475.g002
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parallel study in men [9,21]. However, we did not find an
association between the THFs/THE ratio and BMI and we only
saw a trend towards a positive correlation with waist circumfer-
ence. Notably, the urinary THFs/THE ratio does not distinguish
the activities of 11bHSD type 1 and 2, the latter which catalyses
the deactivation of cortisol to cortisone. Moreover, the changes in
5a-THF/5b-THF ratio and of 5b-THF/cortisol ratio in post-
menopausal women raise the possibility of confounding effects due
to variation in 5b-reductase activity. Increased 5b-reductase would
be expected to decrease, rather than increase, the plasma cortisol
values after oral cortisone. With the hepatic cortisone-to-cortisol
conversion-test data in mind we therefore conclude that there is
increased liver 11bHSD1 activity after the menopause but this
may not be the only reason for alterations in urinary cortisol
metabolite ratios. There is thus a need for further studies using
isotopically labelled cortisol to evaluate whole body 11bHSD1
enzyme activity [34].
Unfortunately we did not have the opportunity to assess visceral
adipose tissue expression and activity of 11bHSD1. This would
have been most interesting especially with regard to the
redistribution of adipose tissue commonly seen with menopause
with increased abdominal depots. Although animal studies
indicate higher 11bHSD1 levels in the visceral adipose tissue, at
least with obesity, some human studies have shown higher
expression in the subcutaneous depot [20,35–41].
In accordance with previous studies in transgenic mice [11–13]
we found that, overall, higher 11bHSD1 was associated with
higher blood pressure and a less beneficial blood lipid profile;
higher total cholesterol, low-density lipoprotein, and triglycerides
and lower high-density lipoprotein, which links to increased risk of
cardiovascular disease. However, we did not find any associations
with insulin or glucose. Rather, the lower HOMA-IR indices
found in postmenopausal women was mainly due to lower fasting
insulin levels in this group. Interestingly, insulin secretion is lower
in postmenopausal vs. premenopausal women and this may
contribute to our finding [42]. However, this observation may also
be explained by genetic factors, diet and/or exercise habits, since
the older women have managed to remain lean past the
menopause. It should thus be considered that by recruiting
normal weight postmenopausal women we may have introduced a
bias in this cohort.
In conclusion, we suggest that menopause/older age linked to
central fat distribution in normal weight women is associated with
increased tissue-specific glucocorticoid exposure via 11bHSD1.
This may contribute to dysmetabolic changes linked to the
increased risk of cardiovascular disease in postmenopausal women.
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